http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29565283

Outgoing Links

Predicate Object
contentType Comment|Journal Article
endingPage 353
issn 1744-7631
1472-8222
issueIdentifier 3
pageRange 351-353
publicationName Expert Opinion on Therapeutic Targets
startingPage 351
bibliographicCitation Antoniu SA. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. Expert Opin Ther Targets. 2011 Mar;15(3):351–3. doi: 10.1517/14728222.2011.550880. PMID: 21208134.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40d8e927677a2a619c5816b256a3469d
date 2011-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1517/14728222.2011.550880
https://pubmed.ncbi.nlm.nih.gov/21208134
isPartOf https://portal.issn.org/resource/ISSN/1744-7631
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27020
https://portal.issn.org/resource/ISSN/1472-8222
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11626560
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6650
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b23065537a07b03ba7e2ca1197841172
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243164928

Total number of triples: 25.